Firmonertinib plus chemo for advanced EGFR-mutant lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new targeted pill (Firmonertinib) combined with standard chemotherapy for stage III lung cancer that cannot be removed by surgery. It is for people with a specific EGFR mutation, and the goal is to see if the combo helps shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III lung cancer that cannot be removed with surgery (confirmed by biopsy).
- Your tumor has a specific EGFR PACC mutation (a genetic change) found by a lab test.
- You have not had any previous treatment for this cancer, like chemo, radiation, or other therapies.
- You have at least one tumor that can be measured on a scan and has not been treated with radiation.
- You are 18 years or older and your overall health is reasonably good (able to do light activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted therapy pill (firmonertinib) given before and after surgery for stage II–III lung adenocarcinoma that has an EGFR mutation. The goal is to see if this approach can shrink the tumor before surgery and reduce the chance of cancer coming back.
This trial tests whether a higher dose of the targeted pill firmonertinib (160 mg) can better control advanced lung cancer in people who have a specific EGFR mutation and whose disease remained stable after a lower dose for 8 weeks. The goal is to see if the higher dose improves outcomes.
This trial tests whether combining the targeted pill firmonertinib with radiation therapy can help people with stage III non-small cell lung cancer that has certain rare EGFR mutations. It is for those whose cancer cannot be removed by surgery.
This trial tests a targeted therapy (firmonertinib) combined with standard chemotherapy before surgery, to see if it can shrink tumors and improve outcomes for people with early-stage lung cancer that has a specific EGFR gene change.
This study tests an oral targeted therapy (firmonertinib) as the first treatment for advanced EGFR-mutated non-small cell lung cancer. It uses blood tests (ctDNA) to see if the drug is working and to guide whether to continue or adjust treatment, aiming to improve outcomes while reducing side effects.
This trial compares a new targeted therapy pill (firmanertinib) to standard chemotherapy in people with advanced non-small cell lung cancer whose tumors have a specific EGFR mutation (PACC or L861Q). If you haven't had treatment for advanced disease and your cancer matches these mutations, this study may offer a more convenient oral option.
Hear when a new EGFR Positive Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.